Yayınlar & Eserler

Yayın Ağı
Makaleler 43
Tümü (43)
SCI-E, SSCI, AHCI (41)
SCI-E, SSCI, AHCI, ESCI (42)
Scopus (43)
TRDizin (1)

1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

SÜTCÜOĞLU O., Akdoğan O., Onur İ. D., Çiftçi A., Alkan A., Majidova N., et al.
Discover Oncology , cilt.17, sa.1, 2026 (SCI-Expanded, Scopus)

2. PRR11 expression in early ER+/HER2‑low breast cancer: Association with estrogen receptor positivity and exploratory analysis of prognostic significance

Turkel A., DOĞAN M., Irkkan S. C., ERDEM H. B., BOZDOĞAN N., Bahsi T.
Oncology Letters , cilt.32, sa.3, 2026 (SCI-Expanded, Scopus) Creative Commons License

3. Domain-Level Distribution of Pathogenic BRCA1/2 Somatic Mutations Shows No Evidence of Large Subtype-Specific Enrichment in Breast Cancer: A Three-Cohort Analysis Supporting Broad BRCA Testing

Sertesen Çamöz E., YILDIZ F., DOĞAN M., Terzi Y. K., Yılmaz Çelik Z.
Genes , cilt.17, sa.6, 2026 (SCI-Expanded, Scopus)

4. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.
International Journal of Cancer , cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)

5. Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group

Telli T. A., Tatlı A. M., ALAN Ö., Keskin G. Y., KARADURMUŞ N., KARAKAYA S., et al.
Clinical Lung Cancer , cilt.26, sa.8, 2025 (SCI-Expanded, Scopus)

6. The Prognostic Impact of HER2 Status and Survival Outcomes in Metastatic Triple Negative Breast Cancer

Turkel A., BAYDAR E., Çolak R., Öztürk A. E., Şakalar T., Akbaş S., et al.
In Vivo , cilt.39, sa.6, ss.3617-3625, 2025 (SCI-Expanded, Scopus)

7. Efficacy of Anti-VEGF and Anti-EGFRs in Microsatellite Instable (MSI-H) Metastatic Colorectal Cancer in a Turkish Oncology Group (TOG) Cohort Study †

Deliktaş Onur İ., DOĞAN M., Öztürk M. A., ŞAHİN T. K., Kiracı M., Arslan A. M., et al.
Current Oncology , cilt.32, sa.11, 2025 (SCI-Expanded, Scopus) Creative Commons License

8. Locoregional Treatment in De Novo Bone-Only Metastatic Breast Cancer: Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a

Soran A., Göktepe B., Demirors B., Aytac O., Ozbas S., DOĞAN L., et al.
Current Oncology , cilt.32, sa.10, 2025 (SCI-Expanded, Scopus) Creative Commons License

9. Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Kahraman S., Erul E., GÜMÜŞAY Ö., GÜVEN D. C., AKSOY S., BAŞARAN G., et al.
Clinical Breast Cancer , cilt.25, sa.5, 2025 (SCI-Expanded, Scopus)

10. “Pre-Treatment“ and “Post-Treatment” Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Yaşar S., Kadıoğlu A., Akyildiz A., Sever N., Büyükbayram M. E., BİLİCİ M., et al.
Medicina (Lithuania) , cilt.61, sa.6, 2025 (SCI-Expanded, Scopus) Creative Commons License

11. ASO Visual Abstract: Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in the NEOSENTITURK-trials MF18-02/18-03

Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., GÜLÇELİK M. A., URAS C., et al.
Annals of surgical oncology , cilt.32, sa.5, ss.3345-3347, 2025 (SCI-Expanded, Scopus)

12. COEXISTING DIAGNOSES OF IATROGENIC CUSHING'S SYNDROME AND PYODERMA GANGRENOSUM DUE TO INAPPROPRIATE TOPICAL CORTICOSTEROID USAGE IN AN OLDER PATIENT

Kars M. Y., DOĞAN M., Dikmeer A., Cordan I., Tekin F. H., KIZILARSLANOĞLU M. C.
Acta Endocrinologica , cilt.21, sa.2, ss.265-271, 2025 (SCI-Expanded, Scopus)

13. Breast Cancer Recurrence in Initially Clinically Node-Positive Patients Undergoing Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in the NEOSENTITURK-Trials MF18-02/18-03

Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., GÜLÇELİK M. A., URAS C., et al.
Annals of Surgical Oncology , cilt.32, sa.2, ss.952-966, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases

Kahraman S., KARAKAYA S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports , cilt.14, sa.1, 2024 (SCI-Expanded, Scopus)

15. Efficacy and safety of bevacizumab in patients with low-grade serous ovarian cancer

Karacin C., Sunar V., Urakci Z., YILMAZ A., Ayhan M., ERSOY M., et al.
Future Oncology , cilt.20, sa.4, ss.207-214, 2024 (SCI-Expanded, Scopus)

16. Predictive Roles of Ki 67 level & mPEPI Score for Neoadjuvant ‘Chemotherapy’ Efficacy in Locally Advanced ER(+)/HER2(-) Breast Cancer

DOĞAN M., Karacin C., Kaman O., Bulut Z. M., Kiziltan G., Oksuzoglu B., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.3, ss.123-130, 2024 (SCI-Expanded, Scopus)

17. Higher TP53 somatic mutation prevalence from liquid biopsy analysis in ever smoker non-small-cell lung cancer patients

ERDEM H. B., Alay M. T., Özdemir Z., Çevik E., ATEŞ Ö., Karaçin C., et al.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , cilt.828, 2024 (Scopus)

18. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.
BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

19. The Prognostic and Functional Impact of Sprouty 2 Expression in Non-small Cell Lung Cancer

Acikgoz Y., Yildirim F. U., Esen S. A., Ucar G., Ergun Y., BAL Ö., et al.
American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.46, sa.12, ss.543-550, 2023 (SCI-Expanded, Scopus)

20. Gemcitabine-associated digital necrosis in metastatic breast cancer

Türkel A., ÖZDEMİR M., Kurtuluş A., DOĞAN M.
Journal of Oncology Pharmacy Practice , cilt.29, sa.7, ss.1770-1775, 2023 (SCI-Expanded, Scopus)

21. Uncommon variants detected via hereditary cancer panel and suggestions for genetic counseling

Özdemir Z., Çevik E., Öksüzoğlu Ö. B. Ç., DOĞAN M., ATEŞ Ö., Esin E., et al.
Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis , cilt.827, 2023 (SCI-Expanded, Scopus)

22. Is the serum level of survivin, an antiapoptotic protein, a potential predictive and prognostic biomarker in metastatic pancreatic cancer?

DEMİRCİ N. S., Çavdar E., ERDEM G. U., Hatipoglu E., Celik E., Sezer S., et al.
Medicine (United States) , cilt.102, sa.25, 2023 (SCI-Expanded, Scopus)

23. The Potential Prognostic Marker TyG Index Predicts Time to Brain Metastasis at HER2 Positive Breast Cancer

KARADAĞ İ., KARAKAYA S., AKKAN T., Demir B., Alkurt E. G., DOĞAN M.
Cancer Management and Research , cilt.15, ss.311-317, 2023 (SCI-Expanded, Scopus)

24. The relationship between hemoglobin-RDW ratio and clinical outcomes in patients with advanced pancreas cancer

İLhan A., GÜRLER F., YILMAZ F. H., Eraslan E., DOĞAN M.
European Review for Medical and Pharmacological Sciences , cilt.27, sa.5, ss.2060-2067, 2023 (SCI-Expanded, Scopus)

25. Intervention for Hepatic and Pulmonary Metastases in Breast Cancer Patients: Prospective, Multi-institutional Registry Study–IMET, Protocol MF 14-02

Soran A., Ozbas S., ÖZÇINAR B., Isik A., DOĞAN L., ŞENOL K., et al.
Annals of Surgical Oncology , cilt.29, sa.10, ss.6327-6336, 2022 (SCI-Expanded, Scopus)

26. Ischemia-Modified Albumin (IMA) levels in ectopic pregnancy and early pregnancy loss

DOĞAN K., Helvacioglu C., Baghaki S., KURAL A., DOĞAN M.
Nigerian Journal of Clinical Practice , cilt.25, sa.7, ss.975-978, 2022 (SCI-Expanded, Scopus)

27. Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

Ergün Y., Uçar G., Aktürk Esen S., Bardakçi M., Kalkan Z., Urakçi Z., et al.
Journal of Oncological Science , cilt.8, sa.2, ss.100-106, 2022 (Scopus, TRDizin)

28. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

Ergun Y., Esen S. A., Bardakci M., Ucar G., Kalkan Z., Urakci Z., et al.
Cancer Biomarkers , cilt.34, sa.2, ss.329-336, 2022 (SCI-Expanded, Scopus)

29. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Karacin C., EREN T., Zeynelgil E., İMAMOĞLU G. İ., ALTINBAŞ M., KARADAĞ İ., et al.
Future Oncology , cilt.17, sa.33, ss.4447-4456, 2021 (SCI-Expanded, Scopus)

30. The Effect of Primary Surgery in Patients with De Novo Stage IV Breast Cancer with Bone Metastasis Only (Protocol BOMET MF 14-01): A Multi-Center, Prospective Registry Study

Soran A., DOĞAN L., Isik A., Ozbas S., Trabulus D. C., Demirci U., et al.
Annals of Surgical Oncology , cilt.28, sa.9, ss.5048-5057, 2021 (SCI-Expanded, Scopus)

31. Easier and more explanatory indices by integrating leukocyte lymphocyte ratio (LLR) and prognostic nutritional index (PNI) to IPS systems in cases with classical Hodgkin lymphoma

PAYDAŞ S., Lacin S., DOĞAN M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., et al.
Leukemia Research , cilt.107, 2021 (SCI-Expanded, Scopus)

32. “Swords and Shields” against COVID-19 for patients with cancer at “clean” and “pandemic” hospitals: are we ready for the second wave?

Karacin C., Acar R., BAL Ö., EREN T., ŞENDUR M. A. N., Acikgoz Y., et al.
Supportive Care in Cancer , cilt.29, sa.8, ss.4587-4593, 2021 (SCI-Expanded, Scopus)

33. Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?

Akkus M. H., Kaman O., DOĞAN M.
Journal of Oncology Pharmacy Practice , cilt.27, sa.5, ss.1251-1254, 2021 (SCI-Expanded, Scopus)

34. IPS-3 Validation in 1012 cases with classical hodgkin lymphoma

PAYDAŞ S., Laçin S., DOĞAN M., BARIŞTA İ., Yildiz B., SEYDAOĞLU G., et al.
Leukemia Research , cilt.102, 2021 (SCI-Expanded, Scopus)

35. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Bahçeci A., PAYDAŞ S., AK N., Ferhatoğlu F., SAİP P. M., SEYDAOĞLU G., et al.
Cancer Investigation , cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded, Scopus)

36. Effectiveness of bendamustine in relapsed or refractory lymphoma cases: A Turkish oncology group study

KARADURMUŞ N., PAYDAŞ S., Esin E., Surmeli Z. G., Yildiz B., ERTÜRK İ., et al.
Archives of Medical Science , cilt.17, sa.4, ss.920-927, 2021 (SCI-Expanded, Scopus) Creative Commons License

37. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥ 75) patients

Alkan A., Güç Z. G., Gürbüz M., Özgün G., Değirmencioğlu S., DOĞAN M., et al.
Journal of Men's Health , cilt.17, sa.4, ss.128-134, 2021 (SCI-Expanded, SSCI, Scopus)

38. Albumin-To-Alkaline Phosphatase Ratio: Does It Predict Survival in Grade 1 and Grade 2 Neuroendocrine Tumors?

Acikgoz Y., BAL Ö., DOĞAN M.
Pancreas , cilt.50, sa.1, ss.111-117, 2021 (SCI-Expanded, Scopus)

39. Is there any clinical or laboratory predictive factor for cetuximab-induced skin toxicity?

Acikgoz Y., BAL Ö., Ucar G., Durnali A., Ergun Y., Dirikoc M., et al.
Expert Opinion on Drug Safety , cilt.20, sa.5, ss.611-621, 2021 (SCI-Expanded, Scopus)

40. The prognostic value of tumor/lymph node standardized uptake value max ratio and correlation with hematologic parameters in stage III nonsmall cell lung cancer

Açikgoz Y., GÜRLER F., Inci B. K., Ergun Y., Ucar G., Dirikoc M., et al.
Medicine (United States) , cilt.99, sa.48, 2020 (SCI-Expanded, Scopus)

41. Endpoints in oncology clinical trials

Kilickap S., Demirci U., KARADURMUŞ N., DOĞAN M., Akinci B., ŞENDUR M. A. N.
Journal of B.U.ON. , cilt.23, ss.1-6, 2018 (SCI-Expanded, Scopus)

42. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Bozkaya Y., Uncu D., DAĞDAŞ S., ERDEM G. U., DOĞAN M., Özet G., et al.
Indian Journal of Hematology and Blood Transfusion , cilt.33, sa.3, ss.361-369, 2017 (SCI-Expanded, Scopus)

43. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis

Bozcuk H., Abali H., Coskun S., Aydiner A., Çinkaya A., Demirkazik A., et al.
World Journal of Surgical Oncology , cilt.10, 2012 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma
Metrikler

Yayın

43

Yayın (WoS)

42

Yayın (Scopus)

43

H-İndeks (WoS)

9

Atıf (Scopus)

314

H-İndeks (Scopus)

10

Proje

1

Tez Danışmanlığı

3

Açık Erişim

8
BM Sürdürülebilir Kalkınma Amaçları
SDG 3: AMAÇ 3: SAĞLIKLI BİREYLER